Cocrystal Pharma, Inc. Operating Income Loss

• Cocrystal Pharma, Inc. showed an increase of +49.6% in Operating Income Loss from 2024 to 2025.
• This data is from Cocrystal Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), Cocrystal Pharma, Inc.'s Operating Income Loss has declined by 28,044.8%.
• Historical annual values: Fiscal year 2025: -$9.02 million | Fiscal year 2024: -$17.88 million | Fiscal year 2023: -$18.56 million | Fiscal year 2022: -$38.83 million | Fiscal year 2021: -$14.22 million | Fiscal year 2020: -$9.59 million | Fiscal year 2019: -$48.41 million | Fiscal year 2018: -$62.92 million | Fiscal year 2017: -$8.26 million | Fiscal year 2016: -$105.82 million | Fiscal year 2015: -$53.95 million | Fiscal year 2014: -$5.80 million | Fiscal year 2013: -$4.08 million | Fiscal year 2012: -$2.55 million | Fiscal year 2011: -$3.89 million | Fiscal year 2010: -$32.0 thousand.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026